This mdr is being submitted due to the study subject participant reported adverse event (ae) of recurrent prolapse.There was no reports of device failure at the time of index and follow up surgery.The acell device was not explanted.A review of the manufacturing records for this lot identified no deviations in the production process.The device was manufactured and distributed sterile in compliance with fda, state, local laws and regulations, and acell's operating procedures.
|
On 6/19/2019 acell, inc.Received an adverse event through the (b)(6) registry from our (b)(6) postmarket surveillance studies on transvaginal pelvic mesh placement for the treatment of pelvic organ prolapse (pop).During the evaluation of the adverse event, we learned that the product solyx (boston scientific) was also involved in the incident.The study subject is experiencing continuing recurrent prolapse following pelvic floor repair with an acell's device and boston scientific solyx product.The index pop repair procedure was conducted on (b)(6) 2018 and the adverse event onset was (b)(6) 2019.Additional surgical treatment was performed on (b)(6) 2019.There was no procedural complication at the time of index and follow up surgery.The acell device was not explanted.
|